Table 5.
Interventions | No. of trials [references] | No. of participants | Weighted mean difference (95% confidence interval) | P value |
RYR vs. no intervention/placebo | ||||
Zhibituo vs. no intervention | 1 [22] | 62 | -0.16 (-0.71 to 0.39) | 0.57 |
RYR supplement vs. placebo | 1 [7] | 83 | -1.04 (-1.38 to -0.70) | < 0.00001 |
Xuezhikang vs. placebo | 4 [8, 24–26] | 323 | -0.74 (-0.93 to -0.55) | < 0.00001 |
Zhibituo vs. placebo | 1 [29] | 205 | -0.20 (-0.53 to 0.13) | 0.24 |
RYR vs. statins | ||||
Xuezhikang vs. simvastatin | 13 [6, 30–34, 36–38, 40–43] | 1238 | 0.14 (-0.05 to 0.33)* | 0.14 |
Xuezhikang vs. pravastatin | 7 [44–50] | 587 | -0.09 (- 0.20 to 0.02)* | 0.11 |
Xuezhikang vs. lovastatin | 3 [51–53] | 191 | 0.00 (- 0.26 to 0.27) | 0.98 |
Xuezhikang vs. atorvastatin | 1 [54] | 60 | 0.20 (-0.10 to 0.50) | 0.19 |
Xuezhikang vs. fluvastatin | 1 [55] | 118 | 0.14 (-0.10 to 0.38) | 0.26 |
Zhibituo vs. simvastatin | 8 [32, 56–62] | 601 | 0.22 (0.04 to 0.39) | 0.02 |
Zhibituo vs. provastatin | 1 [22] | 62 | -0.11 (-0.60 to 0.38) | 0.66 |
Zhibituo vs. lovastatin | 1 [57] | 45 | 0.03 (-0.30 to 0.36) | 0.86 |
RYR vs. non-statin drugs | ||||
Xuezhikang vs. inositol nicotinate | 4 [66–68, 70] | 299 | -0.63 (-0.96 to -0.30) | 0.0002 |
Xuezhikang vs. fenofibrate | 3 [32, 74, 76] | 220 | -0.10 (-1.05 to 0.85)* | 0.84 |
Xuezhikang vs. gemfibrozil | 3 [77–79] | 152 | -0.34 (-0.58 to -0.10) | 0.005 |
Xuezhikang vs. fish oils | 1 [81] | 95 | -0.89 (-1.41 to -0.37) | 0.0008 |
Xuezhikang vs. conjugated estrogens | 1 [85] | 44 | -0.10 (-0.43 to 0.23) | 0.55 |
Xuezhikang vs. biphenalbid | 1 [87] | 64 | -0.06 (-0.32 to 0.20) | 0.65 |
Zhibituo vs. fish oils | 5 [97–101] | 489 | -0.57 (-0.70 to -0.45) | < 0.00001 |
Zhibituo vs. fenofibrate | 1 [32] | 90 | 0.3 1 (0.04 to 0.58) | 0.02 |
RYR vs. RYR | ||||
Xuezhikang vs. Zhibituo | 5 [32, 106, 108, 109, 111] | 628 | -0.08 (-0.18 to 0.02) | 0.12 |
* Random effects model